文献速递泌尿生殖与妇科肿瘤放疗

弥散加权磁共振成像预测宫颈癌放化疗后结局

Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-11-17

本研究回顾性分析69例接受根治性放化疗的宫颈癌患者治疗前MRI,评估原发肿瘤平均ADC值是否独立于已知影像和临床预后因素预测生存。多因素分析显示,较高ADC值、较高分期和非鳞状组织学是疾病无进展生存的独立预测因素。结论认为ADC值是唯一独立预测疾病无进展生存的影像特征,但需进一步验证。

要点

  • 治疗前原发肿瘤平均ADC值较高与疾病无进展生存改善独立相关(HR 0.36,95%CI 0.15-0.85,P=.02)。
  • 较高分期(HR 2.4,95%CI 1.1-5.5,P=.033)和非鳞状组织学(HR 0.23,95%CI 0.07-0.82,P=.024)也是疾病无进展生存的独立预测因素。
  • ADC值是唯一独立预测疾病无进展生存的影像特征,但需进一步验证其识别高复发风险患者的价值。

核心结论

  • 治疗前MRI原发肿瘤平均ADC值是接受放化疗的宫颈癌患者疾病无进展生存的独立预测因素。
  • ADC值是否可用于识别高复发风险的宫颈癌患者尚需进一步验证。

研究设计与样本

  • 回顾性研究,纳入2011至2013年间69例新诊断并接受根治性放化疗的宫颈癌患者。
  • 治疗前使用1.5-T磁共振扫描仪采集包括弥散加权成像序列的MRI,在原发宫颈癌感兴趣区测量平均ADC值。
  • 采用Cox比例风险检验进行单因素和多因素分析,探讨临床和影像变量与疾病控制及生存终点的关联。

主要发现

  • 中位随访16.7个月(范围3.1-44.2个月),1年总生存率、局部区域无复发生存率和疾病无进展生存率分别为91%、86%和74%。
  • 原发肿瘤ADC值中位数为0.941×10-3 mm2/s(范围0.256-1.508×10-3 mm2/s),原发肿瘤标准化摄取值中位数为15(范围6.2-43.4)。
  • 多因素分析中,较高ADC值(HR 0.36,95%CI 0.15-0.85,P=.02)、较高分期(HR 2.4,95%CI 1.1-5.5,P=.033)和非鳞状组织学(HR 0.23,95%CI 0.07-0.82,P=.024)是疾病无进展生存的独立预测因素。

临床怎么用

  • 治疗前MRI测量的原发肿瘤平均ADC值可作为宫颈癌放化疗后疾病无进展生存的预后参考指标。
  • 结合ADC值、分期和组织学类型有助于识别可能高复发风险的患者,但ADC值的临床 utility 需进一步验证。

局限性

  • 回顾性研究,样本量69例,中位随访仅16.7个月。
  • ADC值识别高复发风险患者的价值尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether apparent diffusion coefficient (ADC) value is predictive of survival after definitive chemoradiation for cervical cancer independent of established imaging and clinical prognostic factors. METHODS AND MATERIALS: Between 2011 and 2013, the pretreatment MRI scans for 69 patients treated with definitive chemoradiation for newly diagnosed cervical cancer were retrieved. Scans were acquired with a 1.5-T magnetic resonance scanner, including diffusion-weighted imaging sequences. Mean ADC value was measured within a region of interest in the primary cervical cancer on the baseline MRI scan. Baseline tumor maximum standardized uptake value on positron emission tomography/computed tomography was determined by the reading radiologist. Treatment included external beam radiation therapy to the pelvis followed by brachytherapy in 97%, and with concurrent weekly cisplatin in 99% of patients. Univariate and multivariate analyses were done to investigate the association of clinical and imaging variables with disease control and survival endpoints using a Cox proportional hazard test. RESULTS: Median follow-up was 16.7 months (range, 3.1-44.2 months). The 1-year overall survival, locoregional recurrence-free survival, and disease-free survival rates were 91%, 86%, and 74%, respectively. The median ADC value was 0.941 × 10-3 mm2/s (range, 0.256-1.508 × 10-3 mm2/s). The median standardized uptake value in the primary tumor was 15 (range, 6.2-43.4). In multivariate analysis, higher ADC value (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.15-0.85, P=.02), higher stage (HR 2.4, 95% CI 1.1-5.5, P=.033), and nonsquamous histology (HR 0.23, 95% CI 0.07-0.82, P=.024) were independent predictors of disease-free survival. CONCLUSIONS: The mean ADC value of the primary tumor on pretreatment MRI was the only imaging feature that was an independent predictor of disease-free survival in cervical cancer patients treated with chemoradiation. Further validation will be needed to determine whether ADC values may prove useful in identifying cervical patients at high risk of recurrence.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ho JC, Allen PK, Bhosale PR, et al. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation. Int J Radiat Oncol Biol Phys. 2016. PMID: 28011045. doi:10.1016/j.ijrobp.2016.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。